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SUMMARY 
 
 
Bacterial pathogens use various strategies to interfere with host cell functions. 
Among these strategies, bacteria modulate host gene transcription, thereby modifying the 
set of proteins synthetized by the infected cell. Bacteria can also target pre-existing host 
proteins and modulate their post-translational modifications or trigger their degradation. 
Analysis of protein levels variations in host cells during infection allows to integrate both 
transcriptional and post-transcriptional regulations induced by pathogens. Here, we 
focused on host proteome alterations induced by the toxin Listeriolysin O (LLO), secreted 
by the bacterial pathogen Listeria monocytogenes. We showed that a short-term treatment 
with LLO remodels the host cell proteome by specifically decreasing the abundance of 149 
proteins. The same decrease in host protein levels was observed in different epithelial cell 
lines but not in macrophages. We show in particular that this proteome remodeling affects 
several ubiquitin ligases and that LLO leads to major changes in the host ubiquitylome. 
Strikingly, this toxin-induced proteome remodeling involves only post-transcriptional 
regulations, as no modification in the transcription levels of the corresponding genes was 
observed. In addition, we could show that Perfringolysin O, another bacterial pore-forming 
toxin similar to LLO, also induces host proteome changes. Taken together, our data reveal 
that different bacterial pore-forming toxins induce important host proteome remodeling, 
that may impair epithelial cell functions. 
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INTRODUCTION 
 
Bacterial pathogens have developed many strategies to exploit host functions for survival, 
replication and escape from immune responses. A first strategy consists in interfering with host 
cell protein activities (1-3). Another strategy is to remodel host cell composition, for example by 
modifying the abundance of specific proteins. This remodeling of host cell proteome may result 
from deregulation of gene transcription, which involves the targeting of transcription factors or 
chromatin remodelers (4), or from protein degradation. This degradation can be achieved by 
targeting cellular factors to host degrading machineries such as the proteasome. Conversely, in 
order to respond to infection and to trigger anti-bacterial responses, host cells use similar 
processes, i.e. modulation of the activity of pre-existing components or remodeling of cell 
proteome.  
Characterization of the variations in host cell protein abundance in response to infection is 
thus critical to understand host-pathogen interactions (5). Transcriptional profiling has been 
extensively used to study host cell responses to infections. mRNA concentrations are in this case 
used as proxies to evaluate the concentration of the corresponding proteins. In this context, it is 
assumed that transcript abundance correlates with protein abundance. However, it is now clear 
that protein abundance is strongly dependent on post-transcriptional mechanisms, which include 
stability of the RNA, its export rate to the cytosol, its translation efficiency by ribosomes, as well 
as the stability of the corresponding protein once synthetized (6). Proteomics approaches focusing 
on the direct quantification of proteins rather than RNA, are, in comparison, more informative as 
they integrate all these parameters (5). 
? 4 
Here, we monitored host proteome changes induced by the toxin Listeriolysin O (LLO) 
secreted by the bacterial pathogen Listeria monocytogenes. Listeria is a Gram-positive bacterium 
responsible for the foodborne disease listeriosis, a leading cause of death due to food-transmitted 
bacterial pathogens. Although the vast majority of human infections occur by ingestion of 
contaminated food, some unusual cases of nosocomial infections have been reported. Listeria is a 
facultative intracellular pathogen that can infect both phagocytic and non-phagocytic cells, such 
as epithelial cells. In contrast to the numerous reports of global transcriptional changes induced 
by Listeria in host cells during infection (7-14), only few studies reported post-transcriptional 
alterations of host protein abundance (15-19). These studies focused on specific host proteins (i.e. 
UBC9, TERT, MFF, MRE11 or lysosomal proteins), and did not address whether global 
proteome alterations were induced by the bacterium. Interestingly, the decrease of some of these 
host targets, such as UBC9 or MRE11, is triggered by the pore-forming toxin LLO and was 
shown to be beneficial for Listeria infection (15, 18). 
In order to obtain a complete picture of how the LLO toxin may impact the host cell 
proteome, we decided to use a combination of transcriptomic and proteomic-based approaches to 
monitor the expression level and the fate of host proteins in cells after exposure to the toxin. We 
identified a significant decrease in the levels of 149 host proteins in response to a short treatment 
with LLO. Strikingly, no variation in the transcription level of the corresponding genes was 
observed, indicating that LLO induces remodeling of the host proteome via post-transcriptional 
mechanisms. We identified several components of the host ubiquitin machinery as being 
downregulated by LLO. Consistently, we observed a massive alteration of the host ubiquitylome 
in response to LLO. We finally show that the alterations of protein abundances detected in 
epithelial cells were not observed in macrophages, but were similarly triggered by another 
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cholesterol-dependent pore-forming toxin secreted by the extracellular bacterial pathogen 
Clostridium perfringens. 
 
EXPERIMENTAL PROCEDURES 
Cell culture 
HeLa (American Type Culture Collection (ATCC) CCL-2), Hep G2 (ATCC HB-8065) and RAW 
264.7 (ATCC TIB-71) cells were cultivated at 37°C in a 10% CO2 atmosphere in Minimum 
Essential Medium (MEM) (Invitrogen). Culture media for HeLa and Hep G2 cells were 
supplemented with 2 mM Glutamax (Invitrogen), 10% Fetal Bovine Serum (FBS), MEM non-
essential aminoacids (Invitrogen) and 1 mM sodium pyruvate. Culture medium for RAW 264.7 
was supplemented with 4 mM Glutamax, 10% FBS and 1 mM sodium pyruvate. 
For stable isotope labelling by amino acids in cell culture (SILAC)? (20, 21), HeLa cells were 
cultivated in DMEM without L-lysine, L-arginine, or L-glutamine (Silantes Gmbh) and 
supplemented with 10% dialyzed FBS (Life Technologies vitrogen), 2 mM GlutaMAX (Life 
Technologies), and either natural L-lysine HCl (Lys0) and L-arginine HCl (Arg0) (light labelling; 
Sigma-Aldrich) or D4 L-lysine HCl (Lys4), 13C6 L-lysine HCl (Lys6) and 13C6 L-arginine HCl 
(Arg6) (heavy labelling; Silantes Gmbh). L-Lysine HCl was added at its normal concentration in 
DMEM (146 mg/L), but the concentration of L-arginine HCl was reduced to 25 mg/L (30% of 
the normal concentration in DMEM) to prevent metabolic conversion of arginine to proline. Cells 
were kept for at least six population doublings to ensure complete incorporation of the labelled 
lysine and arginine. 
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Bacterial strains 
Listeria strains were grown in brain heart infusion (BHI) broth or agar plates (BD Difco) at 37°C. 
Strains used in this study were L. monocytogenes EGD (BUG 600) and the corresponding 
isogenic deletion mutant EGD Δhly (BUG 3650; ref. 22). 
 
Bacterial infections 
For in vitro infections, HeLa cells were seeded at a density of 5x105 cells per 960 mm2 wells the 
day before infection. Bacteria were cultured overnight at 37 °C, then sub-cultured 1:20 in BHI 
until exponential-phase (OD600 nm of 1.0), and washed 4 times in PBS. HeLa cells were serum-
starved for 2 hours before infection. 4x107 viable bacteria were added to cells (multiplicity of 
infection (MOI) of 50) and centrifuged on cells for 5 min at 200xg. After 1 h of infection, cells 
were washed and harvested, or incubated for four additional hours with fresh medium 
supplemented with 10% FBS and 50 μg/ml gentamicin (Euromedex) to kill extracellular bacteria. 
 
Pore-forming toxin treatment 
Wild-type and pore-deficient LLO and PFO toxins were purified from Escherichia coli strains 
transformed with plasmids encoding hexahistidine tagged, signal peptide deficient versions of 
LLO and PFO, as described in refs. 15, 22 and 23. Toxins were isolated from E. coli bacterial 
lysates using NiNTA pull-down. The degree of purification for each toxin was checked by SDS-
PAGE analysis followed by Coomassie blue staining. Purified toxins were added directly in 
culture medium of cells serum-starved for 2 hours as indicated in the text. For untreated controls, 
cell culture medium only was added. 
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Experimental design and statistical rationale 
For SILAC-based proteomic analysis, two independent biological replicates were analyzed. For 
label-free proteomic analysis, four independent biological replicates were analyzed. For 
transcriptomic analysis, RNA from three independent biological replicates were analyzed. For 
immunoblot analysis, cell lysates from at least two independent biological replicates were 
analyzed. 
 
Proteomics samples preparation and LC-MS/MS analysis 
For the SILAC-based proteomic analyses, HeLa cells were cultivated in light or heavy SILAC 
media (1.2x107 cells per SILAC condition). Cells were serum-starved for 2 hours and then 
incubated with 3 nM of purified toxin for 20 min or left untreated. For the first SILAC 
experiment (experiment SILAC#1), cells grown in light medium (Lys0, Arg0) were left untreated, 
while cells grown in heavy medium (Lys4, Arg6) were incubated with LLO. Labelling was 
swapped for the second SILAC experiment (experiment SILAC#2): cells grown in light medium 
(Lys0, Arg0) were incubated with LLO, and cells grown in heavy medium (Lys6, Arg6) were left 
untreated. Upon treatment, cells were harvested by scraping on ice in CHAPS lysis buffer (50 
mM sodium phosphate pH 7.4, 100 mM NaCl, 1% CHAPS, complete protease inhibitor tablet 
(Roche)) and lysates from differentially treated light and heavy labelled cells were mixed as 
described above. Mixed lysates were further subjected to 3 freeze-thaw cycles, sonicated and 
incubated with 2.5 U/mL of Micrococcal Nuclease I for 15 min at 37°C. Insoluble components 
were removed by centrifugation for 20 min at 16,000xg and guanidinium hydrochloride (Gu.HCl) 
was added dry to the soluble fraction to a final concentration of 2 M. Proteins were reduced and 
alkylated by incubation with 15 mM tris(2-carboxyethyl)phosphine (TCEP) and 30 mM 
iodoacetamide for 30 min at 37°C. Proteins were desalted on disposable NAP-10 columns (GE 
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Healthcare), boiled for 5 min, put on ice for 5 min and digested overnight with sequencing-grade 
trypsin (Promega, enzyme/substrate of 1/100 (w/w)) at 37°C. The resulting peptide mixture was 
dried completely in a vacuum concentrator, re-dissolved in 0.1% TFA, 0.5% H2O2, and incubated 
for 30 minutes at 30°C to oxidize methionine residues. Samples were snap-frozen, dried 
completely in a vacuum concentrator and re-dissolved in peptide OFFGEL stock solution for 
fractionation into 24 fractions by isoelectric focusing using 24 cm Immobiline DryStrip pH 3-10 
in an Agilent 3100 OFFGEL device, according to the instructions of the manufacturer. 
Fractionated peptides were purified on Omix C18 tips (Agilent), dried and re-dissolved in 20 µl 
loading solvent (0.1% formic acid in water/acetonitrile (98:2, v/v)) of which 10 µl was injected 
for LC-MS/MS analysis on an Ultimate 3000 HPLC system in-line connected to an LTQ Orbitrap 
Velos mass spectrometer (Thermo). Trapping was performed at 10 μl/min for 4 min in loading 
solvent on a PepMapTM C18 column (0.3 mm inner diameter × 5 mm (Dionex)), and following 
back-flushing from the trapping column, the sample was loaded on a reverse-phase column 
(made in-house, 75 µm I.D. x 150 mm, 3 µm beads C18 Reprosil-HD, Dr. Maisch). Peptides 
were eluted by a linear increase from 2 to 55% MS solvent B (0.08% formic acid in 
water/acetonitrile (2:8, v/v)) over 30 minutes at a constant flow rate of 300 nl/min. The mass 
spectrometer was operated in data-dependent mode, automatically switching between MS and 
MS/MS acquisition for the ten most abundant ion peaks per MS spectrum. Full-scan MS spectra 
(300-2000 m/z) were acquired at a resolution of 60,000 in the orbitrap analyzer after 
accumulation to a target value of 1000,000. The ten most intense ions above a threshold value of 
5000 were isolated for fragmentation by CID at a normalized collision energy of 35% in the 
linear ion trap (LTQ) after filling the trap at a target value of 5000 for maximum 50 ms. 
For label-free proteomic analyses, 6x106 HeLa cells were cultivated for each condition in regular 
culture medium. Cells were serum starved for 2 hours and then incubated with 3 nM of purified 
? 9 
LLO for 20 min or left untreated. For proteasome inhibition, cells were pre-incubated for 5h with 
10 µM Lactacystin (Sigma-Aldrich) and 10 µM MG132 (Sigma-Aldrich) and then treated or not 
with LLO. Upon treatment, cells were harvested by scraping on ice in lysis buffer (50 mM 
HEPES pH 8.0, 8M Urea, phosphatases inhibitor (PhosSTOP; Roche)). The protein concentration 
in the lysates was measured and 500 µg of protein from each sample material was isolated to 
continue the protocol. Proteins were reduced by addition of 5 mM DTT and incubation for 30 
minutes at 55˚C and then alkylated by addition of 100 mM iodoacetamide for 15 minutes at room 
temperature in the dark. Samples were further diluted with 50 mM HEPES pH 8.0 to a final urea 
concentration of 4 M and proteins were digested with 5 µg LysC (Wako) (1/100, w/w) for 4 
hours at 37°C. Samples were again diluted to 2 M urea and digested with 5 µg trypsin (Promega) 
(1/100, w/w) overnight at 37˚C. The resulting peptide mixture was acidified by addition of 1% 
trifluoroacetic acid (TFA) and after 15 minutes incubation on ice, samples were centrifuged for 
15 minutes at 1780 x g at room temperature to remove insoluble components. Next, peptides 
were purified on SampliQ C18 columns (Agilent), dried and re-dissolved in loading solvent 
(0.1% TFA in water/acetonitrile (98:2, v/v)) and approximately 2 µg of each sample was injected 
for LC-MS/MS analysis on an Ultimate 3000 RSLCnano system (Thermo) in-line connected to a 
Q Exactive HF mass spectrometer (Thermo) equipped with a Nanospray Flex Ion source 
(Thermo). Trapping was performed at 10 μl/min for 4 min in loading solvent on a 20 mm 
trapping column (made in-house, 100 μm internal diameter (I.D.), 5 μm beads, C18 Reprosil-HD, 
Dr. Maisch, Germany) and the sample was loaded on a 400 mm analytical column (made in-
house, 75 µm I.D., 1.9 µm beads C18 Reprosil-HD, Dr. Maisch). Peptides were eluted by a non-
linear increase from 2 to 56% MS solvent B (0.1% FA in water/acetonitrile (2:8, v/v)) over 140 
minutes at a constant flow rate of 250 nl/min, followed by a 15-minutes wash reaching 99% MS 
solvent B and re-equilibration with MS solvent A (0.1% FA in water/acetonitrile (2:8, v/v)). The 
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column temperature was kept constant at 50°C in a column oven (CoControl 3.3.05, Sonation). 
The mass spectrometer was operated in data-dependent mode, automatically switching between 
MS and MS/MS acquisition for the 16 most abundant ion peaks per MS spectrum. Full-scan MS 
spectra (375-1500 m/z) were acquired at a resolution of 60,000 in the orbitrap analyzer after 
accumulation to a target value of 3,000,000. The 16 most intense ions above a threshold value of 
13,000 were isolated (window of 1.5 Th) for fragmentation at a normalized collision energy of 
28% after filling the trap at a target value of 100,000 for maximum 80 ms. MS/MS spectra (200-
2000 m/z) were acquired at a resolution of 15,000 in the orbitrap analyzer. The S-lens RF level 
was set at 55 and we excluded precursor ions with single and unassigned charge states from 
fragmentation selection. 
 
Data Processing and Gene Ontology Terms Enrichment Analysis 
Data analysis was performed with MaxQuant (version 1.5.6.5 for the SILAC analyses, version 
1.6.0.16 for the label-free analyses;? ref. 24) using the Andromeda search engine (25) with default 
search settings including a false discovery rate set at 1% on both the peptide and protein level. 
Spectra were searched against the human proteins in the Uniprot/Swiss-Prot database (database 
release version of January 2017 containing 20,172 human protein sequences for the SILAC 
analyses; database release version of September 2017 containing 20,237 human protein 
sequences for the label-free analyses, www.uniprot.org) supplemented with the sequence of 
listeriolysin O (RefSeq WP_003722731.1) with a mass tolerance for precursor and fragment ions 
of 4.5 ppm and 0.5 Da, respectively, during the main search. Enzyme specificity was set as C-
terminal to arginine and lysine, also allowing cleavage at proline bonds and a maximum of two 
missed cleavages. Acetylation of protein N-termini was set as variable modification, while 
carbamidomethyl formation of cysteine residues was set as fixed modifications. Oxidation of 
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methionine residues was set as a variable modification in the label-free analysis and as a fixed 
modification in the SILAC analysis. To enable the identification of SILAC labeled peptides the 
multiplicity was set to two with Lys4/Arg6 or Lys6/Arg6 settings in the heavy channel, allowing 
for a maximum of 3 labeled amino acids per peptide. In both SILAC and label-free analyses, only 
proteins with at least one unique or razor peptide were retained and a minimum ratio count of two 
unique or razor peptides was required for quantification. From the SILAC analyses, for each 
protein the H/L ratio normalized by median subtraction is reported in Suppl. Table S1. For the 
label-free analysis, matching between runs was enabled with a matching time window of 1 
minute and an alignment time window of 20 minutes and proteins were quantified by the 
MaxLFQ algorithm integrated in the MaxQuant software (26). Further data analysis of the label-
free samples was performed with the Perseus software (version 1.5.5.3) after loading the 
proteingroups file from MaxQuant. Proteins only identified by site and reverse database hits were 
removed and protein LFQ intensity values were log2 transformed. Replicate samples were 
grouped, proteins with less than three valid values in at least one group were removed, and 
missing values were imputed from a normal distribution around the detection limit leading to a 
list of 2,972 quantified host proteins in the analysis with LLO treatment (Suppl. Table S2A) and 
3,072 host proteins in the analysis with LLO treatment + MG132 (Suppl. Table S2B). Next, a t-
test was performed (FDR=0.05 and S0=1) to reveal proteins of which the expression level was 
significantly affected by LLO treatment and to generate the volcano plots depicted in Fig 1a. 
Finally, Gene Ontology terms enrichment analyses were performed using Database for 
Annotation, Visualization and Integrated Discovery (DAVID) bioinformatics resources?(27). 
 
Analysis of host gene expression in response to LLO treatment.  
Total RNAs from HeLa cells treated or not with 3 nM LLO for 20 min were extracted using 
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RNeasy kits (QIAGEN). Quality of RNAs was monitored on Agilent RNA Nano LabChips 
(Agilent Technologies). RT on 5 µg of total RNA using oligo(dT) primers and in vitro 
transcription of the cDNA in presence of biotin were performed by using a GeneChip 
Amplification One-Cycle Target Labeling kit according to Affymetrix (Santa Clara, CA) 
standard protocols. Fragmented, biotin-labeled cRNA samples were hybridized on Array Type 
GeneChip Human Genome U133 Plus 2.0. For each condition, three biological replicates were 
hybridized. The cell intensity files were generated with GeneChip Operating Software (GCOS). 
Data analysis was performed by using SPlus ArrayAnalyser software (Insightful, Seattle, WA). 
Statistical analysis to compare experimental condition versus control condition was done by 
using the Local Pool error test (28). The P values (the probability that the variability in a gene 
behavior observed between classes could occur by chance) were adjusted by using the 
Benjamini–Hochberg algorithm. 
 
Antibodies 
Primary antibodies used for immunoblot analysis are described in Suppl. Table S3. Anti-mouse 
and anti-rabbit HRP-conjugated antibodies (AbCys) were used as secondary antibodies. 
 
Immunoblot analysis 
For immunoblot analysis, cells were lysed with Laemmli buffer (125 mM Tris-HCl [pH 6.8], 4% 
SDS, 20% glycerol, 100 mM dithiothreitol [DTT], 0.02% bromophenol blue), boiled for 5 min, 
sonicated and protein content was resolved by SDS polyacrylamide gel electrophoresis. Proteins 
were then transferred on PVDF membranes (GE Healthcare) and detected after incubation with 
specific antibodies using Pierce ECL 2 Western Blotting Substrate (Fisher Scientific). 
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RESULTS 
LLO reshapes the host cell proteome 
In order to characterize host proteome alterations induced by LLO, we used shotgun 
proteomics on HeLa cells treated or not with the LLO toxin. We performed a first analysis using 
SILAC (stable isotope labelling by amino acids in cell culture)? (20). The SILAC approach is 
based on differential isotope labelling of proteins during cell culture by metabolic incorporation 
of essential amino acids (predominantly lysine and arginine) that carry light or heavy isotopes. 
After mixing light and heavy-labelled cell lysates, proteins are subjected to trypsin digestion. The 
resulting peptide mixture is then separated and analyzed by tandem mass spectrometry (MS/MS). 
Proteins are identified by searching the recorded spectra against protein databases, and 
quantification is obtained by comparing light and heavy intensity for each peptide. In our 
experimental set up, we compared the protein content from two differentially labelled cell 
populations: one control population and one population incubated with a sublytic dose of LLO (3 
nM) (7). Cells were exposed to LLO during only 20 min to limit protein level changes resulting 
from transcriptional alterations. We performed two independent experiments with swapped 
SILAC labelling to rule out putative labelling-dependent effects. Among the 1834 proteins that 
were quantified in both experiments, we identified a total of 151 proteins for which protein levels 
were consistently decreased in cells treated with LLO (i.e. with a normalized log2 LLO/control 
ratio < -0.5 in both experiments) (Suppl. Fig. S1 and Suppl. Table S1). These results suggest that 
LLO exposure triggers a remodeling of the host proteome by decreasing the protein level of many 
host factors. 
In addition to this preliminary study, we carried out a second experiment using label-free 
quantitative shotgun proteomics to compare protein abundance in cells treated or not with LLO. 
Four independent biological replicates were included in this second screen in order to perform a 
? 14 
robust statistical analysis of downregulated proteins. Degradation of UBC9, a protein known to 
be degraded upon LLO treatment (15), was monitored in each independent replicate using 
immunoblot analysis to validate LLO treatment efficiency (Suppl. Fig. S2). Among the 2,972 
proteins that were quantified in all independent replicates, we identified a total of 149 proteins 
(5.0 %) for which protein levels were significantly decreased in cells treated with LLO (Fig. 1a 
and Suppl. Table S2A). In contrast to these decreases, only 16 proteins (0.5 %) showed 
significant increased levels in LLO-treated cells. This result confirms that LLO remodels the cell 
proteome mainly by decreasing the level of host targets. 
We then classified proteins displaying decreased levels in response to LLO by gene 
ontology (GO) analysis. By looking at cellular localization, we did not observe any enrichment in 
proteins from specific cell compartments in the list of downregulated proteins relative to the total 
list of quantified proteins. This indicates that LLO-induced downregulation affects different 
cellular compartments and in particular both cytosolic and nuclear proteins. By looking at protein 
functions, we identified that a specific cluster of proteins, annotated “Ubl conjugation pathway”, 
is significantly over-represented in the list of proteins downregulated in response to LLO (Fisher 
exact P value = 1.8x10-2). This suggests that LLO not only interferes with host SUMOylation, as 
previously reported (15, 29), but also targets ubiquitin and other ubiquitin-like modifications. 
By focusing on proteins involved in ubiquitin conjugation, we observed that only some 
components were affected, suggesting a tight selection in LLO-targeted host proteins. For 
example, we could identify several E2 conjugases, such as UBE2B, UBE2L3, UBE2T or 
UBE2V1, that are significantly downregulated in response to LLO whereas others, such as 
UBE2R2 or UBE2Z, remained unaffected. We furthermore observed that non-E2 components of 
the ubiquitin system, such as the two E1 enzymes (UBA1 and UBA6), E3 ligases (including 
HECTD1, HUWE1, RNF20, RNF40, RNF213, STUB1, TRIP12, UBR4 and UHRF1) and 
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deubiquitylases (including OTULIN, OTUB1, UCHL5 and several Ubiquitin carboxy-terminal 
hydrolases [USP]) are unaffected by LLO (Suppl. Table S2A). These results demonstrate that 
LLO-induced downregulation affects specific components of the ubiquitylation machinery, and 
that LLO may thus alter only a subset of the host ubiquitylome (see below). 
In addition to Ubiquitin and SUMO, we identified that the levels of two other ubiquitin-
like modifiers, NEDD8 and UFM1, together with their respective E2 enzymes (UBC12/UBE2M 
and UFC1), decreased in response to LLO (Suppl. Table S2A). This suggests that both 
neddylation and UFMylation constitute other examples of ubiquitin-like modification targeted by 
Listeria during infection. 
 
The LLO-induced host proteome remodeling involves post-transcriptional regulations 
To determine if the observed decrease in protein levels was due to transcriptional changes, 
we used data from a transcriptomic analysis of HeLa cells similarly treated or not with LLO for 
20 min (7). By matching these transcriptomic data with our proteomics data, we could obtain 
information on RNA levels corresponding to 97 of the 149 proteins downregulated by LLO. 
Strikingly, the transcription levels of all these targets were not significantly modified in response 
to LLO (Fig. 1b). Although several genes were identified as being differentially expressed after 
20 min of LLO exposure, none of them code for the proteins displaying decreased levels in LLO 
treated cells. This indicates that the vast majority of LLO-induced host protein level decreases 
occurs post-transcriptionally. This observation is consistent with our experimental setup, that 
used a short treatment with LLO (i.e. 20 min) and that renders variations in protein levels due to 
host transcription alterations unlikely. 
To assess whether the host proteasome was involved in the decreased levels of these 149 
proteins, we repeated our label-free quantitative proteomic analysis on HeLa cells pre-treated 
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with proteasome inhibitors before exposure to LLO. The efficiency of proteasome inhibition was 
validated by monitoring the increase in K48-linked polyubiquitin chains in cells treated with both 
MG132 and lactacystin (Suppl. Fig. S2). Very interestingly, we observed that the vast majority 
(i.e. 83 %) of host proteins identified as strongly downregulated in response to LLO also 
displayed significant decreased levels in the presence of proteasome inhibitors (Fig. 1c and 
Suppl. Table S2B and S2C). This result demonstrates that the majority of observed decrease in 
host protein levels induced by LLO is not due to proteasome-mediated degradation. 
 
To further validate our proteomics data, we performed immunoblot analysis on HeLa cells 
treated with 3 nM LLO for 10 or 30 min and followed the protein level of several host targets 
identified in our different proteomic screens. We confirmed that LLO triggers a strong decrease 
in the level of Cystatin-B (CSTB), poly(rC)-binding protein 1 (PCBP1), 14 kDa phosphohistidine 
phosphatase (PHPT1), peptidyl-prolyl cis-trans isomerase A (Cyclophilin A; PPIA), thioredoxin 
(TXN), the two E2 ubiquitin conjugases UBE2K and UBE2N and the E2 SUMO conjugase 
UBC9 (Fig. 2a). This decrease occurs rapidly after LLO exposure (less than 10 minutes). In 
addition, we confirmed that this effect is proteasome-independent as pre-treatment with 
proteasome inhibitors did not block the LLO-induced decrease in the level of these host proteins 
(Fig. 2a). 
Since LLO was previously reported to induce a transient inhibition of translation in host 
cells (30), we addressed whether the observed decreases in host protein levels were reflecting a 
natural decay of proteins following inhibition of translation. To this end, we blocked translation 
before LLO treatment by pre-incubating HeLa cells with cycloheximide (CHX) for 8 hours. CHX 
treatment alone does not lead to a decrease in the levels of three targeted host proteins, i.e. UBC9, 
UBE2K and UBE2N, indicating that these three proteins have a half-time higher than 8 hours 
? 17 
(Fig. 2b). We furthermore observed a strong decrease in the levels of UBC9, UBE2K and 
UBE2N in cells pre-incubated with CHX and treated with LLO, definitively establishing that the 
decrease in the levels of these proteins occurs post-translationally (Fig. 2b). 
To extend our results to other cell lines, we treated Hep G2, a human liver epithelial cell 
line, and RAW 264.7, a murine macrophage-like cell line with 3 nM LLO for 10 or 30 min. 
Immunoblot analysis of Hep G2 cell lysates showed a strong decrease in response to LLO in the 
level of three targets previously identified in HeLa cells (UBC9, UBE2K and UBE2N) (Fig. 3), 
indicating that LLO induces proteome alterations in different epithelial cell types. In contrast, no 
significant changes in UBC9, UBE2K or UBE2N protein levels were observed in LLO-treated 
RAW 264.7, strongly suggesting that macrophages are resistant to, at least, some LLO-induced 
proteome alterations (Fig. 3). 
 
Host proteome remodeling is triggered during infection by Listeria 
In order to assess whether host proteome alterations observed in response to purified LLO 
are also induced in the context of bacterial infection, we infected HeLa cells with either wild-type 
L. monocytogenes (EGD strain), or an LLO-defective Listeria mutant (EGD Δhly). Cells were 
lysed after 1h or 5h of infection and analyzed by immunoblotting experiments. We confirmed 
that infection with wild-type Listeria induces a decrease in the level of host proteins identified 
previously in our mass spectrometry screens (Fig. 4). This decrease was not observed during 
infection with a Δhly strain, confirming the central role of LLO in this process (Fig. 4). 
 
LLO induces alteration of host protein ubiquitylation 
As our data show that several E2 ubiquitin ligases are downregulated in response to LLO,  
we wondered whether this bacterial toxin alters host protein ubiquitylation. By treating HeLa 
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cells with 3 nM LLO for 10 or 30 min, we observed, using immunoblot analysis with antibodies 
specific for K48- or K63-linked polyubiquitin chains, that this toxin triggers a significant 
decrease in the level of these polyubiquitin chains (Fig. 5a). Pre-treatment of HeLa cells with 
proteasome inhibitors does not block this effect, indicating that these decreases in K48- and K63-
linked polyubiquitin chains are proteasome-independent (Fig. 5a). We then infected HeLa cells 
with wild-type L. monocytogenes or a Δhly strain. We observed a significant decrease in K48- 
and K63-ubiquitylated proteins in cells infected with wild-type Listeria after 5h of infection, but 
not with the LLO-deficient mutant (Fig. 5b). Listeria infection, via LLO production, thus strongly 
interferes with host ubiquitylation, which corroborates the observed decrease in several E2 
ligases levels. 
 
Other bacterial pore-forming toxins induce host proteome alteration  
We previously showed that the pore-forming toxin Perfringolysin O (PFO), secreted by 
the extracellular pathogen Clostridium perfringens, induces a decrease in the level of host UBC9, 
similarly to LLO (15). We here monitored whether PFO alters the level of other host proteins 
such as UBE2N or UBE2K. We treated HeLa cells with PFO and observed that this toxin induces 
a decrease in both UBE2K and UBE2N levels (Fig. 6). The decrease was not observed when cells 
were treated with pore formation-deficient mutants of LLO or PFO toxins (15, 22), indicating 
that host protein downregulation requires plasma membrane pore formation by these toxins (Fig. 
6). These results suggest that host proteome remodeling may occur in response to infection by 
different bacterial pathogens that secrete pore-forming toxins in the extracellular milieu. 
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DISCUSSION 
 
 Within cells, the steady-state protein abundance is strongly dependent on post-
transcriptional processes (6). Proteomics studies quantifying the abundance of thousands of 
proteins now allow researchers to integrate transcription regulation, RNA stability, translation 
efficiency and protein stability. By using such a proteomics approach, we quantified nearly 3,000 
host proteins and showed that the listerial pore-forming toxin LLO remodels the host proteome, 
mostly through downregulation of protein level. Strikingly, the vast majority of protein level 
decreases are not due to transcriptional changes, indicating that proteome remodeling by LLO 
occurs at the post-transcriptional level.  
The observed decrease in the abundance of 149 host proteins triggered by nanomolar 
concentration of LLO is a rapid process that occurs in less than 20 min. Interestingly, in this time-
frame, LLO also affects the transcription of a subset of genes, but none of them code for the 149 
targets identified in this study? (7). Thus, exposure to LLO probably triggers several 
complementary waves of proteome alterations, either by directly targeting pre-existing proteins 
or by modulating RNA levels. In the context of Listeria infection, LLO-induced proteome 
remodeling reflects only one part of the different transcriptional and post-transcriptional changes 
that are triggered by this bacterium. Our results show that LLO-induced host proteome 
remodeling is indeed observed during infection and lasts at least for several hours. For long-term 
infections (i.e. >5 hours), additional proteome alterations might be expected (combining LLO and 
LLO-independent remodeling), leading to a different proteomic profile of the host cells.  
 A previous report showed that LLO induces an arrest in protein synthesis (30). This arrest 
allows intoxicated cells to enter a quiescent-like state, in which minimal energy is consumed 
while plasma membrane damage is repaired (30). A direct consequence of this PFT-induced 
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arrest of protein synthesis is the disappearance of short-lived proteins (30). Here, we show that 
the observed decrease in the abundance of UBE2K, UBE2N and UBC9 is not due to such a 
translation arrest (Fig. 2b). This suggests that these proteins are actively degraded in response to 
infection, albeit in a proteasome-independent manner. Interestingly, we previously identified that 
LLO triggers, in epithelial cells, a permeabilization of host lysosomes and a release of lysosomal 
proteases such as cathepsins in the host cytosol (22). Interestingly, these lysosomal proteases are 
not involved in UBC9 degradation (22). Whether these lysosomal proteases are responsible for 
the LLO-induced degradation of some of the other cytosolic proteins identified here remains to 
be determined. In addition to a release of cathepsins from lysosomes, several host proteases were 
reported to be activated in response to LLO. In lymphocytes, LLO induces cell apoptosis, which 
is characterized by the activation of caspase-3 and caspase-9 (31). In macrophages, this toxin 
induces a calcium influx that activates a calcium-dependent calpain protease, participating to the 
maturation and the release of the pro-inflammatory cytokine IL-1α (32). Recombinant LLO was 
also shown to activate caspase-1 in macrophages and HeLa cells, via the induction of a potassium 
efflux and the NLRP3 inflammasome signaling, which participates in IL-1ß conversion and 
secretion (33, 34). Finally, LLO was shown to activate caspase-7 in macrophages, which 
participates to the protection of the cell against the plasma membrane damages induced by the 
toxin (35). Whether these different host proteases, activated in response to LLO, are involved in 
the downregulation of the proteins identified here remains to be determined. Strikingly, we could 
not detect degradation products of the different LLO targets. This may indicate that protein 
fragments generated after the putative proteolytic cleavage of these targets are rapidly degraded 
by host proteases. This might also suggest that the levels of these targets decrease owing to non-
proteolytic mechanisms, such as leakage outside host cells through the large pores formed by 
LLO (36).  
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 Proteins identified in this study as being downregulated in response to LLO are involved 
in various cellular pathways. In particular, we identified several E2 ubiquitin ligases that were 
affected by the toxin. This result correlates with our observation of a strong alteration of the host 
ubiquitylome, more particularly of proteins modified by K63- and K48-linked ubiquitin chains. 
This result very interestingly echoes the effect of LLO on another ubiquitin-like modification, 
SUMOylation, where the E2 SUMO enzyme UBC9 is degraded in response to the toxin (15). As 
for SUMOylation, ubiquitylation is a very dynamic modification? (37). The observed decrease in 
ubiquitylated proteins probably results from the downregulation of E2 ubiquitin ligases, that 
impairs de novo ubiquitylation, while cellular deubiquitylases remain active and lead to a shift in 
the reaction equilibrium towards the non-ubiquilyated form of the proteins. Interestingly, 
targeting of E2 ubiquitin ligases such as UBE2N has also been reported in the case of the 
intestinal pathogen Shigella flexneri. Indeed, this bacterium secretes an effector, OspI, that 
catalyses the deamidation of UBE2N in HeLa cells. This modification blocks UBE2N activity 
and inhibits acute inflammatory response in the initial stage of infection (38). Thus, UBE2N 
might be a key host factor targeted by different pathogens during infection, albeit by different 
mechanisms. 
In addition to E2 ubiquitin ligases, our data provide a list of other host proteins 
downregulated in response to LLO exposure that may play so far unknown roles during infection. 
Downregulation of some of these candidates may either promote infection, while others may 
dampen infection if their decrease is sensed as a danger signal by the host cell that will then 
trigger anti-bacterial responses.  
Finally, we showed that PFO, another pore-forming toxin secreted by an extracellular 
pathogen, also triggers host proteome remodeling. In addition to LLO or PFO toxins, that both 
belong to the family of cholesterol-dependent cytolysins, it has been shown that the pore-forming 
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toxin α-Hemolysin, secreted by some uropathogenic Escherichia coli (UPEC), also induces 
degradation of specific host proteins involved in cell adhesion, inflammation or cell survival (39). 
This indicates that host proteome remodeling triggered by pore-forming toxins is a widespread 
strategy used by different classes of pathogens. 
Interestingly, Chlamydia trachomatis, an obligate intracellular bacterium, was also reported 
to deeply remodel the host proteome, independently from changes in transcription (40). These 
findings and ours highlight the importance of proteomic-based approaches that focus on protein 
abundance rather than mRNA levels to decipher unknown host-pathogen interactions.  
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FIGURE LEGENDS 
 
Figure 1 : Host proteome alterations induced by LLO 
a, Volcano plot showing host protein level fold changes (in log2) in cells treated with LLO 
compared to control cells (x axis), in the presence or absence of proteasome inhibitors. Four 
independent replicates were analyzed and a t-test was performed to calculate –log P values for 
each protein (y axis). Black lines indicate the boundary of significance as set by the Perseus 
software (FDR=0.05 and S0=1) (Suppl. Table S2A). b, Proteomic and transcriptomic analysis of 
HeLa cells treated with 3 nM LLO for 20 min. Each protein identified in the proteomic screen is 
represented by a dot, whose coordinates reflect changes in RNA and protein levels after exposure 
to LLO. Host factors with significant decrease in protein levels after LLO treatment are 
highlighted in red. c, Comparison of protein level changes after exposure to LLO in cells pre-
treated or not with proteasome inhibitors. Each protein identified as significantly downregulated 
by LLO in the absence of proteasome inhibitors is represented by a dot, whose coordinates reflect 
protein levels changes compared to control cells (in log2), in the presence or absence of 
proteasome inhibitors (Suppl. Table S2B and S2C). 
 
Figure 2 : Proteasome-independent and post-translational alterations of host proteins 
induced by LLO 
a, Immunoblot analysis of HeLa cells pre-treated or not with proteasome inhibitors, and then 
incubated with 3 nM LLO for 10 or 30 min. Antibodies against the following targets were used to 
monitor changes in protein levels : CSTB (Cystatin-B), PCBP1 (Poly(rC)-binding protein 1), 
PHPT1 (14 kDa phospho-histidine phosphatase), PPIA (peptidyl-prolyl cis-trans isomerase A), 
TXN (Thioredoxin), UBE2K (Ubiquitin-conjugating enzyme E2 K), UBE2N (Ubiquitin-
? 29 
conjugating enzyme E2 N) and UBC9 (SUMO-conjugating enzyme UBC9). b, Immunoblot 
analysis of HeLa cells pre-treated or not with cycloheximide (CHX) for 8 h, and then incubated 
with 3 nM LLO for 10 min. Actin is shown as a loading control. 
 
Figure 3 : Cell type specificity of LLO-induced downregulation of host proteins 
Immunoblot analysis of Hep G2 and RAW 264.7 cells incubated with 3 nM LLO for 10 or 30 
min. Antibodies against UBE2K (Ubiquitin-conjugating enzyme E2 K), UBE2N (Ubiquitin-
conjugating enzyme E2 N) and UBC9 (SUMO-conjugating enzyme UBC9) were used to monitor 
changes in protein levels. Antibodies against actin and GAPDH were used as loading controls. 
 
Figure 4 : Host proteome alterations induced by Listeria infection 
Immunoblot analysis of HeLa cells infected for 1 or 5h with wild-type or Δhly Listeria 
monocytogenes. Antibodies against the following targets were used to monitor changes in protein 
levels : CSTB (Cystatin-B), PCBP1 (Poly(rC)-binding protein 1), TXN (Thioredoxin), UBE2K 
(Ubiquitin-conjugating enzyme E2 K), UBE2N (Ubiquitin-conjugating enzyme E2 N) and UBC9 
(SUMO-conjugating enzyme UBC9). Actin is shown as a loading control. 
 
Figure 5 : Host ubiquitylation alteration in response to Listeria infection 
a, Immunoblot analysis of HeLa cells pre-treated or not with proteasome inhibitors, and then 
incubated with 3 nM LLO for 10 or 30 min. b, Immunoblot analysis of HeLa cells infected for 5h 
with wild-type or Δhly Listeria monocytogenes. Antibodies against K48- and K63-linked 
polyubiquitin chains were used to monitor changes in host protein ubiquitination. Actin is shown 
as a loading control. 
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Figure 6 : Pore-formation dependent downregulation of host proteins by LLO and PFO 
Immunoblot analysis of HeLa incubated for 30 min with wild-type (WT) or pore-deficient (mut) 
LLO and PFO toxins. Antibodies against UBE2K (Ubiquitin-conjugating enzyme E2 K), UBE2N 
(Ubiquitin-conjugating enzyme E2 N) and UBC9 (SUMO-conjugating enzyme UBC9) were used 
to monitor changes in protein levels. Actin is shown as a loading control. Wild-type toxins were 
used at similar hemolytic titres. Mutant toxins were used at similar protein concentration as the 
corresponding wild-type toxins. 
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